FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small batches of radio chemicals and radio pharmaceuticals, we meet the need of Bio Pharma scientists and start-up ventures for research materials. This will drive both their ambitions to develop a new drug.
FIELD-LAB is part of a unique and complete nuclear infrastructure.
Read more about Nuclear Infrastructure
Currently, research is done on the production and development of various isotopes:
Read more
Learn more about FIELD-LAB and its importance. Discover our global network for pre-clinical and clinical research: research that is part of the development of every new medical product.
FIELD-LAB is created for and together with partners from different backgrounds. Some of the finest Dutch and British UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society. In addition, the partnerships that arise from FIELD-LAB form a portal to a fast growing network, which results in an open innovation environment.
The new FIELD-LAB establishment, dedicated to the production of medical isotopes for cancer treatment and which opened in December 2023, will operate under GMP standards. According to Harry Hendrikse, a professor Translational Radiopharmacology at Erasmus Medical Center and one of the GMP consultants who initially worked on this project, that is not an easy task.
Erasmus Medical Center in Rotterdam and NRG PALLAS teamed up last years within FIELD-LAB to realise a study on the stability and efficacy of different ligands in combination with Lead-212 for the treatment of NETs. And the results were promising.
Karlijn van der Schilden
R&D Manager Medical Isotopes
T. +31 224 56 8018
M. k.vanderschilden@nrg.eu
Vinod Ramnandanlal
Commercial Director
T. +31 224 56 4196
M. ramnandanlal@nrg.eu